相关实验视频
Updated: Jun 28, 2025

06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
586
[患有2型糖尿病和冠心病的患者患有心力衰竭]
André Scheen1, Nicolas Paquot1, Patrizio Lancellotti2
1Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Liège, Belgique.
Revue medicale de Liege
|April 11, 2024
概括
2型糖尿病患者经常有心脏问题,需要多种药物. 本综述探讨了使用GLP-1受体激动剂和SGLT2抑制剂来控制糖尿病,心脏病发作和心力衰竭,考虑到比利时的补偿规则.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病 (T2D) 患者经常患有心血管相关疾病.
- 管理T2D与并发症需要多药学,针对血糖控制和心血管健康.
- 某些糖尿病药物对血糖控制和心血管/心力衰竭的结果具有双重益处.
研究的目的:
- 讨论T2D患者心肌梗塞和随后的心力衰竭的药物治疗.
- 评估葡萄糖类-1受体激动剂 (GLP-1RA) 和-葡萄糖共传输体-2抑制剂 (SGLT2is) 在治疗心力衰竭的T2D中的作用.
- 分析在这个患者群体中结合GLP-1RA和SGLT2is的潜在好处和挑战,考虑到比利时的补偿限制.
主要方法:
- 临床贴图讨论. 临床贴图讨论.
- 对T2D和心力衰竭的当前药物治疗指南的审查.
- 对血糖控制,心血管预后和心力衰竭结果的药物益处的分析.
- 考虑比利时的具体退款标准.
主要成果:
- GLP-1 RAs和SGLT2is在改善T2D患者的葡萄糖控制,心血管预后和心力衰竭结果方面显示出显著的益处.
- 结合GLP-1RA和SGLT2is可能为患有T2D,心肌梗塞和心力衰竭的患者提供协同效益.
- 比利时的补偿限制可能会限制这些有益的药物类别的可访问性和应用.
结论:
- 对于T2D患者,包括心力衰竭在内的心血管并发症,GLP-1RA和SGLT2is是关键的治疗选择.
- 优化药物治疗需要仔细考虑药物的疗效,患者的并发症和医疗保健系统政策.
- 需要对治疗策略进行进一步评估,以应对报销挑战并最大限度地提高患者的利益.
相关概念视频
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337

